natgillin/translations-raw huggingface dataset:
- in an ampoule (5 ml) for 10 doses in a pack of 50
- ampuli (5 ml) za 10 odmerkov v pakiranju po 50
- in a vial (5 ml) for 10 doses in a pack of 50
- viali (5 ml) za 10 odmerkov v pakiranju po 50
- in a vial (10 ml) for 20 doses in a pack of 50
- viali (10 ml) za 20 odmerkov v pakiranju po 50
For any information about thismedicine, please contact the local representative of the Marketing Authorisation Holder:
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
Ελλάδα GlaxoSmithKline A. E. B. E Tηλ: + 30 210 68 82 100
51 Ελλάδα GlaxoSmithKline A. E. B. E Tηλ: + 30 210 68 82 100
54 This leaflet was last approved in {MM/ YYYY}.
Navodilo je bilo odobreno
DaTSCAN is a solution for injection containing the active substance ioflupane (123I).
Zdravilo DaTSCAN je raztopina za injiciranje, ki vsebuje zdravilno učinkovino ioflupan (123I).
DaTSCAN is used to detect the loss of nerve cells in an area of the brain called the striatum.
Zdravilo DaTSCAN se uporablja za ugotavljanje izgube živčnih celic v določenem predelu možganov, ki se imenuje striatum.
It specifically helps to detect the loss of nerve cells that release dopamine, a chemical messenger.
Zdravilo še zlasti pomaga odkriti izgubo živčnih celic, ki izločajo dopamin, ki je kemični prenašalec.
The medicine is used to help in the diagnosis of: • movement disorders such as those seen in Parkinson’ s disease and other related diseases, where a loss of striatal nerve cells in the brain leads to tremor (shaking), gait disturbance and stiffness of muscles.
Zdravilo se uporablja za pomoč pri odkrivanju in diagnozi: • težav pri gibanju, kakršne se opazijo pri Parkinsonovi bolezni in drugih sorodnih boleznih, kjer izguba živčnih celic striatuma privede do tremorja (tresenja rok), motenj pri hoji in otrplosti mišičja.
But these disorders can also occur in ‘ essential tremor’ (tremor whose cause is not known).
Vendar pa se te motnje lahko pojavijo tudi pri „ esencialnem tremorju “ (tremor, katerega vzrok ni znan).
DaTSCAN is used to help distinguish between a type of dementia known as ‘ dementia with Lewy bodies ’ from Alzheimer’ s disease.
Zdravilo DaTSCAN se uporablja za razločevanje med Parkinsonovo boleznijo in esencialnim tremorjem; • demence (izguba intelektualnih sposobnosti): zdravilo DaTSCAN se uporablja za razločevanje med vrsto demence, ki je znana kot „ demenca z Lewyjevimi telesci “, in Alzheimerjevo boleznijo.
DaTSCAN should only be used in patients who have been referred by a doctor who has experience in the management of movement disorders or dementia.
Zdravilo DaTSCAN lahko uporabljamo le pri bolnikih, ki jim je napotnico izdal zdravnik z izkušnjami v vodenju motenj gibanja ali demence.
DaTSCAN will only be handled and given by people who have experience in the safe handling of radioactive material.
Z zdravilom DaTSCAN lahko rokujejo in ga dajejo le osebe, ki imajo izkušnje z varnim ravnanjem z radioaktivnimi snovmi.
When receiving DaTSCAN, patients must also take another medicine (such as iodine tablets) to prevent their thyroid gland from taking up the iodine contained in DaTSCAN.
Bolniki morajo med prejemanjem zdravila DaTSCAN jemati tudi drugo zdravilo (kakršno so tablete joda), ki njihovi ščitnici preprečuje absorpcijo joda iz zdravila DaTSCAN.
This is taken 1 to 4 hours before and 12 to 24 hours after DaTSCAN.
Drugo zdravilo je treba vzeti 1 do 4 ure pred in 12 do 24 ur po prejemu odmerka zdravila DaTSCAN.
DaTSCAN is given by slow intravenous injection (not less than 15 to 20 seconds) into an arm vein, and a scan is taken 3 to 6 hours after the injection.
Zdravilo DaTSCAN s počasnim intravenskim vbrizgavanjem (trajati ne sme manj kot 15 do 20 sekund) vbrizgamo v veno roke, slikanje pa opravimo 3 do 6 ur po injekciji.
The active substance in DaTSCAN, ioflupane (123I), is a radiopharmaceutical.
Zdravilna učinkovina v zdravilu DaTSCAN je iflupan (123I), ki spada med radiofarmacevtske izdelke.
It contains a substance, ioflupane, that has been labelled with 123I (iodine-123), a radioactive form of the chemical element iodine.
Ta vsebuje spojino imenovano ioflupan, ki je radioaktivno označena z 123I (jod 123), radioaktivno obliko kemičnega elementa imenovanega jod.
When DaTSCAN is injected into a patient, ioflupane (123I) is distributed in the body via the bloodstream and accumulates in the striatum, where it binds to the transporter structures.
Ioflupan se veže na strukture na površini končičev živčnih celic v striatnem območju možganov, ki so odgovorni za prenašanje dopamina.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged (SPECT) that detects the radioactive iodine-123..
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Ko bolniku vbrizgamo zdravilo DaTSCAN, se ioflupan (123I) s krvjo porazdeli po telesu in se zbira v striatumu, kjer se veže na prenašalne strukture.
If there is a loss of nerve cells containing dopamine (as occurs typically in patients with Parkinson’ s disease) the binding of DaTSCAN is greatly reduced and this can be seen on the scan.
Če je prišlo do izgube živčnih celic, ki vsebujejo dopamin (kar je običajen pojav pri bolnikih s Parkinsonovo boleznijo), se sposobnost vezanja zdravila DaTSCAN močno zmanjša, kar se odrazi tudi na nastali sliki.
In Parkinson’ s disease, DaTSCAN has been studied in 254 patients in two studies.
V primeru Parkinsonove bolezni so zdravilo DaTSCAN raziskali v dveh študijah pri 254 bolnikih.
In both studies, images obtained in healthy volunteers (45 in total) were compared to those in patients with Parkinson’ s disease (180 patients) or essential tremor (29 patients).
V obeh študijah so slike, dobljene pri zdravih prostovoljcih (vsega skupaj 45), primerjali s tistimi, dobljenimi pri bolnikih s Parkinsonovo boleznijo (180 bolnikov) ali esencialnim tremorjem (29 bolnikov).
In dementia, DaTSCAN has been studied in 288 patients who had been diagnosed with either dementia with Lewy bodies or Alzheimer’ s disease, as well as some other forms of dementia.
V primeru demence so zdravilo DaTSCAN raziskali pri 288 bolnikih z diagnosticirano demenco z Lewyjevimi telesci ali Alzheimerjevo boleznijo, kot tudi nekaterimi drugimi oblikami demence.
In all studies, the measure of effectiveness was the accuracy of the diagnosis based on the images from the scan compared to the diagnosis made by a specialist doctor.
V vseh študijah je merilo učinkovitosti predstavljala točnost diagnoze, ugotovljene na osnovi slik, v primerjavi z diagnozo, ki jo je ugotovil zdravnik specialist.
What benefit has DaTSCAN shown during the studies?
Kakšne koristi je zdravilo DaTSCAN izkazalo med raziskavami?
In the main study of patients with Parkinson’ s disease and essential tremor, the sensitivity of DaTSCAN was 96.5%.
V glavni študiji pri bolnikih s Parkinsonovo boleznijo in esencialnim tremorjem je bila občutljivost zdravila DaTSCAN 96, 5%.
This means that the disease identified by the doctor reading the images obtained using DaTSCAN matched the existing diagnostic of the patients in 96.5% of cases.
To pomeni, da je bolezen, kot jo je opredelil zdravnik, ki je tolmačil slike, pridobljene ob uporabi zdravila DaTSCAN, ustrezala že obstoječi diagnostični sliki bolnikov v 96, 5%.
The values for the sensitivity of DaTSCAN to distinguish probable dementia caused by Lewy bodies from other types of dementia ranged from 75.0 to 80.2%.
Občutljivost zdravila DaTSCAN pri razločevanju morebitne demence, ki jo povzročajo Lewyjeva telesca, od drugih tipov demence je znašala od 75, 0 do 80, 2%.
Common side effects observed with the use of DaTSCAN are increased appetite, headache, formication (a sensation of something crawling on or under the skin), and vertigo (a spinning sensation).
Pogosti neželeni učinki, ki so jih opazili pri uporabi zdravila DaTSCAN, so povečan tek, glavobol, mravljinčenje in vrtoglavica.
For the full list of all side effects reported with DaTSCAN, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila DaTSCAN, glejte Navodilo za uporabo.
DaTSCAN should not be used in people who may be hypersensitive (allergic) to ioflupane or any of the other ingredients, or in women who are pregnant.
Zdravila DaTSCAN ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ioflupan ali katerokoli drugo sestavino zdravila, ter noseče ženske.
The Committee for Medicinal products for Human Use (CHMP) decided that DaTSCAN’ s benefits are greater than its risks as a diagnostic agent to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’ s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy, and to help differentiate probable dementia with Lewy bodies from Alzheimer ’ s dementia.
Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da so koristi zdravila DaTSCAN večje od z njim povezanih tveganj pri uporabi kot diagnostično sredstvo za pomoč pri razločevanju med esencialnim tremorjem in parkinsonskimi sindromi, ki so povezani z idiopatično Parkinsonovo boleznijo, multiplo sistemsko atrofijo in progresivno supranuklearno paralizo, in v pomoč ločevanju morebitne demence z Lewyjevimi telesci od Alzheimerjeve demence.
The committee recommended that DaTSCAN be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom DaTSCAN.
The marketing authorisation was renewed on 27 July 2005.
Dovoljenje za promet je bilo obnovljeno 27. julija 2005.
The full EPAR for DaTSCAN is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo DaTSCAN je na voljo tukaj.
This summary was last updated in 02-2007.
Ta povzetek je bil nazadnje posodobljen 02- 2007.
EU/ 1/ 00/ 135/ 001
EU/ 1/ 00/ 135/ 001 DaTSCAN
DaTSCAN
o
EU/ 1/ 00/ 135/ 002
EU/ 1/ 00/ 135/ 002 DaTSCAN
DaTSCAN 74 MBq/ ml solution for injection
DaTSCAN 74 MBq/ ml raztopina za injiciranje
Ioflupane (123I) 74 MBq/ ml at reference time (0.07-0.13 μ g/ ml of ioflupane).
Ioflupan (123I) 74 MBq/ ml v referenčnem času (0, 07 – 0, 13 μg/ ml ioflupana).
2.5 ml vials contain 185 MBq and 5 ml vials contain 370 MBq ioflupane (123I) (specific activity range 2.5-4.5 x 1014 Bq/ mmol) at reference time.
2, 5- mililitrske viale vsebujejo 185 MBq in 5- mililitrske viale vsebujejo 370 MBq ioflupana (123I) (obseg specifičnega delovanja 2, 5 – 4, 5 x 1014 Bq/ mmol) v referenčnem času.
This medicinal product contains 5% volume ethanol.
To zdravilo vsebuje volumensko 5% etanola.
For a full list of excipients see section 6.1
Za celoten seznam pomožnih snovi glejte poglavje 6. 1.
Clear colourless solution
Prozirna, brezbarvna raztopina
• In patients with clinically uncertain Parkinsonian Syndromes, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’ s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy.
DaTSCAN je namenjen odkrivanju izgube končičev dopaminergičnih nevronov v striatnem korpusu: • pri bolnikih, pri katerih obstaja sum parkinsonskih sindromov, ter s tem tudi ločevanju esencialnega tremorja od parkinsonskih sindromov, povezanih z idiopatsko Parkinsonovo boleznijo, multiplo sistemsko atrofijo in progresivno supranuklearno paralizo.
DaTSCAN is unable to discriminate between Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. • To help differentiate probable dementia with Lewy bodies from Alzheimer’ s disease.
Z DaTSCANOM ne moremo razločiti Parkinsonove bolezni, multiple sistemske atrofije in progresivne supranuklearne paralize. • V pomoč pri razlikovanju verjetne demence z Lewyjevimi telesci od Alzheimerjeve bolezni.
DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’ s disease dementia.
DaTSCAN ni zmožen ločiti med demenco z Lewyjevimi telesci in demence Parkinsonove bolezni.
DaTSCAN should only be used in patients referred by physicians experienced in the management of movement disorders and/ or dementia.
DaTSCAN uporabljamo le pri bolnikih, ki jih na pregled napotijo zdravniki, izkušeni v zdravljenju motenj gibanja in/ ali demence.
Radiopharmaceutical agents should only be used by qualified personnel with the appropriate government authorisation for the use and manipulation of radionuclides within a designated clinical setting.
Radiofarmacevtske snovi lahko uporablja le usposobljeno osebje z ustreznim vladnim dovoljenjem za uporabo in ravnanje z radionuklidi v ustreznem kliničnem okolju.
DaTSCAN is a 5% (v/ v) ethanolic solution for intravenous injection and should be used without dilution.
DaTSCAN je 5- odstotna (v/ v) raztopina etanola za intravensko injiciranje in se uporablja brez redčenja.
Clinical efficacy has been demonstrated across the range 111-185 MBq.
Klinična učinkovitost DaTSCANA je v območju 111 – 185 MBq.
Do not exceed 185 MBq and do not use when the activity is below 110 MBq.
Ne uporabljajte ga pri aktivnosti, večji od 185 MBq ali manjši od 110 MBq.
In the event of overdosage, refer to section 4.9.
V primeru prevelikega odmerka glejte poglavje 4. 9.
To minimise the potential for pain at the injection site during administration, a slow intravenous injection (not less than 15-20 seconds) via an arm vein is recommended.
2 Da bi zmanjšali morebitno bolečino na mestu injiciranja, priporočamo počasno intravensko injekcijo (ne manj kot 15 – 20 sekund) v veno na roki.
2 Patients must undergo appropriate thyroid blocking treatment prior to injection to minimise thyroid uptake of radioactive iodine, for example by oral administration of approximately 120 mg potassium iodide 1-4 hours prior to injection and again 12-24 hours post-injection of DaTSCAN.
Bolnik mora 1 – 4 ure pred injekcijo in nato 12 – 24 ur po injekciji DaTSCANA opraviti ustrezno terapijo za blokiranje ščitnice, ki zmanjša privzem radioaktivnega joda, na primer po zaužitju približno 120 mg kalijevega jodida.
Images should be acquired using a gamma camera fitted with a high-resolution collimator and calibrated using the 159 keV photopeak and a ± 10% energy window.
Energijska odstopanja so lahko ± 10%.
Experimental studies with a striatal phantom, suggest that optimal images are obtained with matrix size and zoom factors selected to give a pixel size of 3.5-4.5 mm for those systems currently in use.
Poskusi na striatnem fantomu kažejo, da pridobimo najboljše slike s takšno nastavitvijo velikosti matrike in povečave, da je pri sistemih v trenutni rabi velikost slikovne pike med 3, 5 in 4, 5 mm.
Abnormal images are either asymmetric or symmetric with unequal intensity and/ or loss of crescent.
Nenormalne slike so bodisi nesimetrične bodisi simetrične, vendar z neenako intenzivnostjo in/ ali nesrpaste oblike.
DaTSCAN is not recommended for use in children or adolescents due to a lack of data on safety and efficacy.
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba DaTSCANA pri otrocih ali adolescentih ni priporočljiva.
In the absence of data, DaTSCAN is not recommended in cases of moderate to severe renal or hepatic impairment.
Zaradi pomanjkanja podatkov uporabe DaTSCANA ne priporočamo pri bolnikih z zmerno do težko okvaro ledvic ali jeter.
This medicinal product contains 5% volume ethanol (alcohol), up to 197 mg per dose, equivalent to 5 ml beer, 2 ml wine.
To zdravilo vsebuje volumensko 5% etanola (alkohola), do 197 mg po odmerku, kar je enakovredno 5 ml piva ali 2 ml vina.
To be taken into account in high-risk groups such as patients with liver disease or epilepsy.
Vzemite to v poštev pri visoko rizičnih skupinah, kot so bolniki s poškodbo jetr ali epilepsijo.
Medicines that bind to the dopamine transporter with high affinity may therefore interfere with DaTSCAN diagnosis.
Zdravila, ki se z visoko afiniteto vežejo na prenašalce za dopamin, lahko torej vplivajo na diagnosticiranje z DaTSCANOM.
Medicines shown during clinical trials not to interfere with DaTSCAN imaging include amantadine, trihexyphenidyl, budipine, levodopa, metoprolol, primidone, propranolol and selegiline.
Med zdravila, za katera so klinična preskušanja pokazala, da ne vplivajo na slikanje z DaTSCANOM, sodijo amantadin, benzheksol, budipin, levodopa, metoprolol, primidon, propranolol in selegilin.
Dopamine agonists and antagonists acting on the postsynaptic dopamine receptors are not expected to interfere with DaTSCAN imaging and can therefore be continued if desired.
Agonisti in antagonisti dopamina, ki delujejo na postsinaptične dopaminske receptorje, naj na slikanje z DaTSCANOM ne bi vplivali in jih bolniki torej
Drugs shown in animal studies not to interfere with DaTSCAN imaging include pergolide.
Raziskave na živalih so pokazale, da pergolid ne vpliva na slikanje z DaTSCANOM.
DaTSCAN is contraindicated in pregnancy.
Zdravilo DaTSCAN je kontraindicirano med nosečnostjo.
Radionuclide procedures carried out on pregnant women also involve
Pri radionukleidnih postopkih pri nosečnicah prejme določen odmerek sevanja tudi plod.
Administration of ioflupane (123I) at a dose of 185 MBq results in an absorbed dose to the uterus of 3.0 mGy.
Pri uporabi ioflupana (123I), pri odmerku 185 MBq, maternica absorbira odmerek 3, 0 mGy.
A radiation dose above 0.5 mGy would be regarded as a potential risk to the foetus.
Odmerek sevanja, večji od 0, 5 mGy, je lahko za plod nevaren.
Before administering a radioactive medicinal product to a breast-feeding mother, consideration should be given as to whether the investigation could be reasonably delayed until the mother has ceased breast-feeding and as to whether the most appropriate choice of radiopharmaceutical has been made, bearing in mind the secretion of radioactivity in breast milk.
Poleg tega se prepričajte, da ste izbrali najprimernejši radiofarmak; pri tem upoštevajte izločanje aktivnih snovi v mleko.
No studies on the effects on the ability to drive and use machines have been performed.
Niso izvedene študije o vplivu na sposobnost za vožnjo in upravljanje s stroji.
No serious adverse reactions related to DaTSCAN administration have been reported.
Ni poročil o resnih neželenih reakcijah, vezanih na uporabo DaTSCANA.
The following common (≥ 1/ 100 to < 1/ 10) side effects are recognised for DaTSCAN:
Naslednji neželeni učinki so pogosto (≥1/ 100 do < 1/ 10) opaženi pri uporabi DaTSCANA:
Metabolism and nutrition disorders Appetite increased
Presnovne in prehranske motnje Povečan apetit
Nervous system disorders Headache Formication (paraesthesia)
Bolezni živčevja Glavobol Formikacija (mravljinčenje) (parestezija)
Ear and labyrinth disorders Vertigo
Ušesne bolezni, vključno z motnjami labirinta Vrtoglavica
The following uncommon (≥ 1/ 1,000 to ≤ 1/ 100) side effects are recognised for DaTSCAN:
Naslednji neželeni učinki so nepogosto (≥1/ 1. 000 do < 1/ 100) opaženi pri uporabi DaTSCANA:
General disorders and administration site conditions Injection site pain (intense pain following administration into small veins)
Splošne težave in spremembe na mestu aplikacije Bolečine na mestu injiciranja (hude bolečine po injiciranju v majhne žile)
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result.
Uporabljena aktivnost mora biti taka, da je končni odmerek sevanja čim nižji in obenem omogoča želeni diagnostični rezultat.
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.
Izpostavljenost ionizirajočemu sevanju je povezana z nastankom rakastih obolenj in z nevarnostjo dednih okvar.
For diagnostic nuclear medicine investigations, the current evidence suggests that these adverse events will occur with negligible frequency because of the low radiation dose incurred.
Pri diagnostičnih raziskavah v jedrski medicini trenutni podatki kažejo, da do teh neželenih učinkov pride redko, saj so bolniki izpostavljeni nizkim odmerkom sevanja.
In cases of overdosage of radioactivity, frequent micturition and defaecation should be encouraged in order to minimise radiation dosage to the patient.
V primeru prevelikega odmerka sevanja morate spodbujati pogosto uriniranje in odvajanje blata, da bi zmanjšali odmerek sevanja, ki ga je bolnik prejel, na najmanjšo možno mero.
Diagnostic radiopharmaceutical for central nervous system imaging, ATC code:
Radiodiagnostiki za ugotavljanje bolezni osrednjega živčevja, Oznaka ATC:
V09A B 03.
V09A B 03
Due to the low quantities of ioflupane injected, pharmacological effects are not expected following intravenous administration of DaTSCAN at the recommended dosage.
Zaradi nizke količine vbrizganega ioflupana farmakoloških učinkov po intravenski uporabi DaTSCANA v priporočenih odmerkih ne pričakujemo.
Ioflupane also binds to the serotonin transporter on 5-HT neurons but with lower (approximately 10-fold) binding affinity.
Ioflupan se veže tudi na serotoninske prenašalce na 5- HT nevronih, vendar z (približno 10- krat) manjšo afiniteto.
In a pivotal clinical trial including evaluation of 288 subjects with dementia with Lewy bodies (DLB) (144 subjects), Alzheimer’ s disease (124 subjects), vascular dementia (9 subjects) or other (11 subjects), the results of an independent, blinded visual assessment of the DaTSCAN images were compared to the clinical diagnosis as determined by physicians experienced in the management and diagnosis of dementias.
V osrednji klinični študiji, ki je vključevala oceno 288 bolnikov z demenco z Lewyjevimi telesci (DLB) (144 bolnikov), Alzheimerjevo boleznijo (124 bolnikov), vaskularno demenco (9 bolnikov) ter drugih (11 bolnikov), so bili rezultati slepe neodvisne vizualne ocene DaTSCAN slik primerjani s kliničnimi diagnozami, kot so jih diagnosticirali zdravniki, z izkušnjami v zdravljenju in diagnostiricanju demenc.
The values for the sensitivity of DaTSCAN in determining probable DLB from non-DLB ranged from 75.0% to 80.2% and specificity from 88.6% to 91.4%.
Senzitivnost DaTSCANa pri ločevanju verjetne DLB od ne- DLB je bila med 75, 0% in 80, 2%, specifičènost pa med 88, 6% in 91, 4%.
The positive predictive value ranged from 78.9% to 84.4% and the negative predictive value from 86.1% to 88.7%.
Pozitivna napovedna vrednost je bila v intervalu med 78, 9% in 84, 4%, specifičnost negativne napovedne vrednosti pa med 86, 1% in 88, 7%.
Analyses in which both possible and probable DLB patients were compared with non-DLB dementia patients demonstrated values for the sensitivity of DaTSCAN ranging from 75.0% to 80.2% and specificity from 81.3% to 83.9% when the possible DLB patients were included as non-DLB patients.
Analize, pri katerih je bila opravljena primerjava med možnimi in verjetnimi DLB bolniki z bolniki z ne- DLB demenco, so pokazale vednosti senzitivnosti DaTSCANa v mejah med 75, 0% in 80, 2% in specifičnosti med 81, 3% in 83, 9%, v primeru, da so bili bolniki z možno DLB demenco všteti v skupino bolnikov z ne- DLB demenco.
The sensitivity ranged from 60.6% to 63.4% and specificity from 88.6% to 91.4% when the possible DLB patients were included as DLB patients.
V primeru, da so bili bolniki z možno DLB demenco vključeni v skupino bolnikov z DLB demenco, pa je bila senzitivnost v mejah med 60, 6% do 63, 4%, specifičnost pa med 88, 6% do 91, 4%.
Ioflupane (123I) is cleared rapidly from the blood after intravenous injection; only 5% of the administered activity remains in whole blood at 5 minutes post-injection.
Ioflupan (123I) se po intravenskem injiciranju hitro očisti iz krvi; 5 minut po injiciranju ostane v krvnem obtoku le 5% aktivnosti.
Uptake in the brain is rapid, reaching about 7% of injected activity at 10 minutes post-injection and decreasing to 3% after 5 hours.
V 10 minutah po injiciranju doseže približno 7% aktivnosti in po 5 urah pade na 3%.
About 30% of the whole brain activity is attributed to striatal uptake.
Približno 30% celotne aktivnosti v možganih pripisujemo privzemu v striatni korpus.